VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
176.08
+1.12 (+0.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close174.96
Open174.66
Bid171.07 x 1800
Ask179.00 x 800
Day's Range173.59 - 176.99
52 Week Range136.50 - 183.39
Volume963,604
Avg. Volume1,527,253
Market Cap44.999B
Beta1.86
PE Ratio (TTM)109.16
EPS (TTM)1.61
Earnings DateOct 23, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est196.52
Trade prices are not sourced from all markets
  • 4 Winning Stocks With Solid Efficiency Level
    Zacks2 days ago

    4 Winning Stocks With Solid Efficiency Level

    A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

  • Should Vertex Pharmaceuticals (VRTX) Be On Your Radar Now?
    Zacks2 days ago

    Should Vertex Pharmaceuticals (VRTX) Be On Your Radar Now?

    Vertex Pharmaceuticals (VRTX) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

  • Why Vertex Is Expected to Report Robust EPS Growth in 2018
    Market Realist3 days ago

    Why Vertex Is Expected to Report Robust EPS Growth in 2018

    How Is Vertex Pharmaceuticals Positioned in August? In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) reiterated its projection for non-GAAP combined selling, general, and administrative (or SG&A) and research and development (or R&D) expenses to come in in the range of $1.5 billion and $1.55 billion for fiscal 2018. In Q2 2018, the company reported non-GAAP combined R&D and SG&A expenses close to $388 million.

  • Business Wire3 days ago

    Vertex Awards Two College Students Full Scholarships to the University of Massachusetts

    Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride scholarship to pursue an education in science, technology, engineering, art or math (STEAM) at any University of Massachusetts campus.

  • Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth
    Market Realist3 days ago

    Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth

    In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) updated its revenue guidance for fiscal 2018 from the previously projected range of $2.65 billion–$2.8 billion to $2.9 billion–$3.0 billion. The midpoint of this guidance range would imply a 36% year-over-year (or YoY) rise in revenues in fiscal 2018. This expectation has mainly been driven by the solid adoption of Symdeko since its launch in US markets. The company has not assumed the impact of securing new reimbursement for its CF drugs in markets outside the US in its fiscal 2018 revenue guidance.

  • Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
    Zacks3 days ago

    Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

    Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

  • Reuters3 days ago

    Vertex cystic fibrosis drug gets expanded approval for use in infants

    U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months. The expanded approval makes Kalydeco the first medicine to treat the underlying cause of the genetic disease in this age group among patients with specific mutations in the CF transmembrane regulator (CFTR) gene, Vertex said on Wednesday. The drug is currently approved in the United States to treat patients aged 2 and older whose CFTR gene has certain mutations.

  • Business Wire3 days ago

    FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene

    Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to

  • Benzinga4 days ago

    The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 14) DexCom, Inc. (NASDAQ: DXCM ) Masimo Corporation (NASDAQ: MASI ...

  • Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit
    Zacks5 days ago

    Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit

    Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.

  • Benzinga6 days ago

    The Week Ahead: Nvidia, Retailer Earnings In Focus

    Below is a list of notable corporate events for the week beginning August 13. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on NTAP Monday ...

  • 7 Fast-Growing Stocks to Buy Today
    InvestorPlace6 days ago

    7 Fast-Growing Stocks to Buy Today

    If you haven’t noticed, there has been a lot of talk about something that we haven’t heard about for almost a decade — inflation.

  • GlobeNewswire9 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Immunomedics, Vertex Pharmaceuticals, Ralph Lauren, Alliant Energy, TreeHouse Foods, and Lincoln National — New Research Emphasizes Economic Growth

    NEW YORK, Aug. 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Immunomedics, ...

  • Analyst Recommendations for Exelixis in August
    Market Realist10 days ago

    Analyst Recommendations for Exelixis in August

    In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, which was a ~66% YoY (year-over-year) growth. Exelixis’s net product revenues grew 9% sequentially in the second quarter. In the second quarter, Ipsen, Exelixis’s partner, generated cumulative revenues of $150 million from sales of cabozantinib.

  • 7 Biotech Stocks With Big Upcoming Catalysts
    Kiplinger10 days ago

    7 Biotech Stocks With Big Upcoming Catalysts

    Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018

  • Is Crispr Therapeutics Stock Grossly Overvalued?
    Motley Fool10 days ago

    Is Crispr Therapeutics Stock Grossly Overvalued?

    Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?

  • Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2
    Zacks10 days ago

    Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2

    Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.

  • Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
    Zacks10 days ago

    Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise

    Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.

  • 3 Top Biotech Stocks to Buy in August
    Motley Fool10 days ago

    3 Top Biotech Stocks to Buy in August

    It could be the perfect time to add shares in these biotech companies to portfolios ahead of key catalysts.

  • See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX

  • Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
    Zacks11 days ago

    Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

    The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.

  • Business Wire11 days ago

    FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease

    Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF in this population. ORKAMBI oral granules are available in two dosage strengths (lumacaftor 100mg/ivacaftor 125mg and lumacaftor 150mg/ivacaftor 188mg) for weight-based dosing. ORKAMBI oral granules should be available for fulfillment within 2 to 4 weeks.

  • Barrons.com11 days ago

    8 Biotechs Still Worth Buying After a Sector Surge

    Stifel updated its outlook on the biotech sector, and sees reason to be bullish on several big names. While biotech has had its ups and downs, in general this has been a good year to be in the sector: The iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have risen 10.7% and 12.8%, respectively, since the start of 2018, above the broader market and even the gain seen by the increasing popular health-care sector itself, as the Health Care Select Sector SPDR ETF (XLV) is up 8.8% since the start of the year.  While smaller biotechs have benefited more from the moves, there are still some bigger companies that warrant attention, argues Stifel's Paul Matteis. Stifel transferred and initiated coverage on a number of biotech stocks, today, with Buy ratings on Vertex Pharmaceuticals  (VRTX), BioMarin Pharmaceuticals (BMRN), Biogen (BIIB), Alnylam Pharmaceuticals (ANLY), Sage Therapeutics (SAGE), Neurocrine Biosciences (NBIX), Wave Life Sciences (WVE), and Alder BioPharmaceuticals (ALDR).

  • Analysts Are Bullish on Sarepta Therapeutics
    Market Realist12 days ago

    Analysts Are Bullish on Sarepta Therapeutics

    Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.

  • This stock sector most often beats analysts’ estimates
    MarketWatch12 days ago

    This stock sector most often beats analysts’ estimates

    Sixty-one of 63 health-care companies have exceeded analysts’ estimates when they reported their most recent results.